(Reuters) - The U.S. Securities and Exchange Commission's top enforcement chief warned on Tuesday that too many pharmaceutical companies are failing to accurately portray their dealings with federal drug regulators - a problem that could get them in trouble.
Andrew Ceresney, the SEC's enforcement director, said the agency has seen a lot of problems with disclosures by pharmaceutical companies, including on 8-Ks - a form companies file when they need to disclose an event that is "material" to their business. more
No comments:
Post a Comment